JAN 27, 2021 4:38 AM PST

Does intermittent fasting reduce the risk of postmenopausal breast cancer?

New research in mouse models suggests that intermittent fasting could reduce the risk of metastasis of breast cancer tumors. The research from scientists at the University of California San Diego School of Medicine, Moores Cancer Center, and Veterans Affairs San Diego Healthcare System (VASDSH) shifts the emphasis of breast-cancer specific diets from the what-to-eat to the when-to-eat. The findings are published in the most recent edition of the journal Nature Communications.

Time-restricted eating that aligns nutrient intake with circadian rhythms of when bodies are at their most active has been investigated for the purposes of weight loss. But this research suggests that aligning metabolic rhythms could also reduce cancer development in mice with obesity-driven postmenopausal breast cancer.

"Previous research has shown that obesity increases the risk of a variety of cancers by negatively affecting how the body reacts to insulin levels and changing circadian rhythms," said senior author Nicholas Webster, Ph.D., professor at UC San Diego School of Medicine and senior research career scientist at VASDSH. "We were able to increase insulin sensitivity, reduce hyperinsulinemia, restore circadian rhythms and reduce tumor growth by simply modifying when and for how long mice had access to food."

More specifically, the team compared the outcomes of mice that were restricted to eating only during an eight-hour period and mice that access to food all day. The third group of mice in the experiment were given an unrestricted low-fat diet.

"Time-restricted eating has a positive effect on metabolic health and does not trigger the hunger and irritability that is associated with long-term fasting or calorie restriction," first author Manasi Das, Ph.D. "Through its beneficial metabolic effects, time-restricted eating may also provide an inexpensive, easy to adopt, but effective strategy to prevent and inhibit breast cancer without requiring a change in diet or physical activity."

Photo: Pexels

The authors suggest that given their findings, time-restricted eating could be a strategy worth pursuing in human clinical trials due to its ability to modulate hyperinsulinemia.

"The increase in risk of breast cancer is particularly high in women who are overweight and have been through menopause. For this reason, doctors may advice women to adopt weight-loss strategies to prevent tumor growth," said Das. "Our data suggest that a person may benefit from simply timing their meals differently to prevent breast cancer rather than changing what they eat."

Sources: Nature Communications, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
DEC 02, 2020
Cancer
Investigating the Active Components of an Herbal Mushroom
DEC 02, 2020
Investigating the Active Components of an Herbal Mushroom
When people think of traditional medicine, often what comes to mind are the old herbal medical practices in Asian countr ...
DEC 23, 2020
Cancer
Using AI to identify new measures of mammography
DEC 23, 2020
Using AI to identify new measures of mammography
New findings published in the International Journal of Cancer from the University of Melbourne report that new mamm ...
JAN 11, 2021
Cancer
Sentinel Nodes Could Reveal a Tumor's Prognosis
JAN 11, 2021
Sentinel Nodes Could Reveal a Tumor's Prognosis
For many diseases, the ability to quickly and effectively diagnose or prognose a patient is critical. If caught early on ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
FEB 04, 2021
Cancer
Microchip models tumor‐immune interactions to predict immunotherapy effectiveness
FEB 04, 2021
Microchip models tumor‐immune interactions to predict immunotherapy effectiveness
A team from the Terasaki Institute for Biomedical Innovation (TIBI) has developed a microchip system that models immune ...
FEB 17, 2021
Clinical & Molecular DX
Urine Test Bypasses the Need for Prostate Biopsies
FEB 17, 2021
Urine Test Bypasses the Need for Prostate Biopsies
Researchers have created a urine test for prostate cancer that could make unnecessary biopsies a thing of the past. The ...
Loading Comments...